title: Ipilimumab-induced autoimmune pancytopenia in a case of metastatic melanoma.
abstract: A 77-year-old patient treated with ipilimumab (anti-CTLA-4 antibody) for metastatic melanoma developed autoimmune pancytopenia (anemia, thrombocytopenia, and neutropenia) 8 days after the fourth infusion. This pancytopenia was resistant to high-dose oral corticosteroids (1 mg/kg) and to hematopoietic growth factors. It resolved after intravenous immunoglobulins injection. To date, only 1 case of autoimmune pancytopenia has been reported after this treatment. According to the case that we report, it seems essential to control the leukocyte count before any injection of ipilimumab.
authors.affiliation: Departments of *Dermato-Oncology †CIC Biotherapy INSERM U892, Hôtel-Dieu University Hospital, Nantes, France.
authors.forename: Pauline
authors.initials: P
authors.lastname: du Rusquec
authors.forename: Melanie
authors.initials: M
authors.lastname: Saint-Jean
authors.forename: Anabelle
authors.initials: A
authors.lastname: Brocard
authors.forename: Lucie
authors.initials: L
authors.lastname: Peuvrel
authors.forename: Amir
authors.initials: A
authors.lastname: Khammari
authors.forename: Gaelle
authors.initials: G
authors.lastname: Quéreux
authors.forename: Brigitte
authors.initials: B
authors.lastname: Dréno
mesh_terms: D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects; D001327:Autoimmune Diseases / Q000209:etiology*; D060908:CTLA-4 Antigen / Q000276:immunology; D005260:Female; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000008:administration & dosage; D007167:Immunotherapy / Q000009:adverse effects*; D000074324:Ipilimumab; D007958:Leukocyte Count; D008545:Melanoma / Q000150:complications / Q000276:immunology / Q000628:therapy*; D008991:Monitoring, Physiologic; D009362:Neoplasm Metastasis; D010198:Pancytopenia / Q000209:etiology*; D020127:Recovery of Function; D012878:Skin Neoplasms / Q000150:complications / Q000276:immunology / Q000628:therapy*
chemical_list: D000911:Antibodies, Monoclonal; D060908:CTLA-4 Antigen; D016756:Immunoglobulins, Intravenous; D000074324:Ipilimumab